DailyMed Label Puts THERAWORX Foot Cramp Roll-On in the Homeopathic Category
The latest DailyMed labeling for THERAWORX RELIEF FOR FOOT CRAMPS ROLL ON places the product squarely in the category of an unapproved homeopathic OTC drug. The label identifies magnesium sulfate as the active ingredient, presented as 6X 0.05% HPUS, with topical administration and a purpose framed around “muscle cramp & soreness relief.” The product is packaged as a 74 mL bottle under NDC 61594-041-00 and lists AVADIM HOLDINGS, INC. as both labeler and registrant.
The regulatory posture matters as much as the ingredient list. The label carries a direct disclaimer that the product has not been evaluated by the Food and Drug Administration for safety or efficacy, and it states that FDA is not aware of scientific evidence supporting homeopathy as effective. For clinicians, pharmacists, and patients, that language is not ornamental. It defines how the product should be interpreted: as a marketed topical homeopathic preparation, not as an evidence-based treatment with established comparative benefit for foot cramps.
Foot cramps are often abrupt, painful, and difficult for patients to self-manage, particularly when they strike at night or recur in the setting of repetitive activity, dehydration, or other contributing factors. A roll-on product may appeal because it is simple to apply and local in intent, and the label is designed around that bedside logic. Yet the presence of a topical vehicle does not itself establish pharmacologic efficacy. A compound applied to skin still has to demonstrate a plausible mechanism, reproducible symptom relief, and acceptable safety before it can be viewed as more than a consumer-facing comfort product.
What the Label Says About Use, Safety, and Boundaries
The labeling directs users to shake well, roll a thin layer over each impacted muscle group, allow it to air dry, and repeat as needed. It also states that the product is safe to use daily. Those directions are straightforward, but the safety section is more revealing than the consumer-use language around it. The product is for external use only, eye contact should be avoided, and if contact occurs, the area should be rinsed thoroughly with water. It also should not be ingested.
A brief caution appears for patients who are pregnant or breastfeeding, advising them to ask a health professional before use. The label instructs users to stop use and ask a doctor if unintended effects occur, and it warns to keep the product out of reach of children. If swallowed, medical help or poison control should be contacted right away. These are standard precautions for a topical OTC product, but they also reflect the broader reality of home-use treatments: even products marketed for localized relief can cause avoidable harm if misused, especially in children or in households where topical products are stored casually.
Storage guidance is also specified, with a temperature range of 32°F to 120°F. The inactive ingredient list is extensive and includes allantoin, aloe vera leaf extract, aloe vera leaf juice, water, benzyl alcohol, citric acid monohydrate, cocamidopropyl betaine, silver, glycerin, lauryl glucoside, PEG/PPG-4/12 dimethicone, potassium sorbate, sodium benzoate, edetate sodium, alpha-tocopherol acetate, xanthan gum, and yeast, among others. In practical terms, those excipients signal a formulation built to spread smoothly, dry on contact, and preserve product stability rather than to establish therapeutic proof.
One sentence carries the entire evidentiary burden here: FDA has not accepted scientific support for homeopathy as effective.
Magnesium Sulfate on the Skin and the Evidence Gap Behind the Marketing Claim
Magnesium plays a well-known role in neuromuscular physiology, and magnesium deficiency can contribute to muscle irritability in certain clinical settings. That biological familiarity may make a magnesium-containing topical product feel intuitively credible to consumers experiencing cramps. Still, topical delivery is a different proposition from systemic replacement. Skin is a barrier, and the labeling provides no clinical trial data showing that this magnesium sulfate cream changes cramp frequency, shortens cramp duration, or improves post-cramp soreness in a measurable way.
The homeopathic designation further complicates interpretation. The active ingredient is listed as 6X 0.05% HPUS, a description that places the product in a homeopathic framework rather than in the conventional prescription or standard OTC model. For clinicians counseling patients, the practical implication is simple: a product can be widely marketed for a symptom and still lack the kind of scientific validation that would justify recommending it as a first-line treatment. Patients who perceive short-term relief may be responding to massage, counter-irritant sensation, placebo effect, or the natural self-limited course of a cramp episode rather than to a proven biochemical action of the ingredient itself.
That distinction becomes especially relevant when foot cramps are recurrent, unilateral, associated with weakness, or tied to medications or systemic illness. In those settings, symptom management should not obscure the need to consider dehydration, electrolyte disturbance, neuropathy, peripheral vascular disease, medication effects, or other causes that belong on the differential diagnosis. A roll-on product may sit at the margin of comfort care, but it should not displace evaluation when the pattern of cramping is clinically atypical.
Packaging, Label History, and the Current Regulatory Snapshot
DailyMed lists a marketing start date of April 1, 2024, and shows the current label version published October 16, 2026, with an earlier version dated April 2, 2024. The product is identified as a human OTC drug with no DEA schedule. The label archive and RSS feed entries indicate ongoing cataloging within the federal drug-labeling system, but none of that changes the central regulatory fact attached to the product: it remains categorized as an unapproved homeopathic drug.
For patients scanning a pharmacy shelf, the distinction between a soothing topical preparation and an evidence-based medical therapy can be easy to miss. For clinicians, it is more direct. The product is marketed for foot cramp and soreness relief, but the label itself does not establish clinical efficacy, and the FDA disclaimer explicitly warns against assuming that homeopathic labeling equals scientific validation. If a patient prefers to try it, the discussion should be framed around low-risk external use, the possibility of skin irritation or unintended exposure, and the more important question of whether the cramp pattern warrants a medical workup rather than repeated symptomatic self-treatment.
In the end, the label reads less like a clinical endorsement than a regulatory boundary marker. It identifies the ingredients, the intended topical use, and the homeopathic status, while simultaneously warning that efficacy has not been established in the way patients often assume when they reach for a product promising relief from painful muscle cramps.